FDA Approves Ahzantive (aflibercept-mrbb), a Biosimilar to Eylea
FDA approves FYB203/Ahzantive® (aflibercept-mrbb), a biosimilar to Eylea®, for treating nAMD, DME, DR, and RVO, inhibiting VEGF. FYB203/Ahzantive® demonstrated comparable efficacy and safety to Eylea®, with global sales of around US$ 9 billion in 2023. A marketing authorization application for FYB203 was submitted to the EMA, with a decision expected by early 2025.
Highlighted Terms
Related News
FDA Approves Ahzantive (aflibercept-mrbb), a Biosimilar to Eylea
FDA approves FYB203/Ahzantive® (aflibercept-mrbb), a biosimilar to Eylea®, for treating nAMD, DME, DR, and RVO, inhibiting VEGF. FYB203/Ahzantive® demonstrated comparable efficacy and safety to Eylea®, with global sales of around US$ 9 billion in 2023. A marketing authorization application for FYB203 was submitted to the EMA, with a decision expected by early 2025.